Rothein Pharmaceuticals Catopli tablets through the consistency evaluation of generic drugs

The Catopli tablet consistency evaluation reference preparation was developed by Baishi Mei Shiguibao, for the first competitive angiotensin conversion enzyme inhibitor varieties, by preventing the conversion of angiotensin subtype to reduce peripheral vascular resistance, used to treat hypertension and heart failure, after oral 1-1.5 hours can reach the peak concentration of blood medicine in the bodythere are a number of pharmaceutical companies in China have produced katopli tablets listed, belonging to Class A medical insurance drugsOver the past three years, the research and development staff of the Roxin Pharmaceuticals Katopli tablet project has screened out high-efficiency and stable prescription processes through a variety of different process studies, and finally, various product indicators, including efficacy stability, dissolved curve, etc., have reached the same level with the original drug, and passed and referenced the bioequivalence of the preparation at one timeThis approval will not only help to enhance the market competitiveness of the variety in the national drug collection plan, but also accumulate valuable experience for the company's follow-up consistency evaluationAt present, the company's injection of lansolaquine and other remaining 7 products have completed the generic drug consistency evaluation declaration;in addition to the high-quality generic drug consistency evaluation and declaration work, Luoxin Pharmaceuticals also actively promote the new 4 types of generic drug research and development, marketLuo Xin Pharmaceuticals announced that it will continue to adhere to the combination of imitation, innovation-driven research and development, is committed to creating more generic drugs equivalent to the original research drug pipeline, while focusing on the layout of innovative drug pipeline, through the continuous improvement of the competitiveness of superior products and high value-added products life cycle, for the vast number of patients to provide more and better drug optionsSource: Luo Xin PharmaceuticalS Bulletin